We are proud to announce a remarkable milestone for Universiti Malaya Medical Centre (UMMC) in the ZENITH High Proteinuria (D4325C00010) study. Under the leadership of Assoc. Prof. Dr. Wong Chew Ming and Study Coordinator Ms. Marhainie Mohammad, the team has achieved exceptional results, pushing the boundaries of clinical research in chronic kidney disease (CKD).
The ZENITH High Proteinuria study, a Phase III trial, evaluates innovative treatments for participants with CKD and high proteinuria.
Key Achievements Include:
- First site in Malaysia to recruit a subject.
- Top recruiters in Malaysia, achieving ~225% of the initial recruitment target.
- Successfully reached the last patient in (LSI) 7 months ahead of schedule, setting a record pace in recruitment.
This incredible accomplishment follows the recent AstraZeneca visit on 9 October, where Assoc. Prof. Dr. Wong was recognized for his exceptional work in randomizing over five patients.
We extend our heartfelt gratitude to Assoc. Prof. Dr. Wong, Ms. Marhainie, and the UMMC team for their unwavering commitment and dedication to improving outcomes for CKD patients. Together, we are making significant strides in clinical research and patient care.